Marcela Maus, M.D., Ph.D.

At-Large Director


Dr. Maus has extensive experience in the biology of T cell activation and clinical translation of gene-modified T cells. She has 20+ years of basic laboratory research experience in T cell biology, and is board-certified in Internal Medicine, Medical Oncology and in Hematology, and attends on the bone marrow transplantation service. She has unique expertise in bringing novel cell and gene therapies from the laboratory to the clinic, including the local and federal regulatory processes mandated for translation of gene and cell therapies. Leading multi-disciplinary teams of scientists and clinicians, she has successfully opened trials of genetically-modified T cells in multiple myeloma, leukemia, mesothelioma, pancreatic, and ovarian cancers, and glioblastoma multiforme.

In her position at the Massachusetts General Hospital Cancer Center, Dr. Maus runs a laboratory that focuses on innovative forms of T cell engineering in the pre-clinical setting and in mechanistic studies in pre-clinical models and with patient-derived samples. Dr. Maus directs the Cellular Immunotherapy Program at MGH, and oversees the clinical and translational research portfolio in T cell therapies at MGH. She is a national and international figure in the field, having leadership roles in the Society of Immunotherapy for Cancer, Keystone Symposia, American Society of Cell and Gene Therapy, Foundation for Accreditation of Cell Therapies, European Society of Medical Oncology, and American Society of Hematology. She participates as a faculty member on training grants such as F30, F31, T32, and K12 to mentor graduate students and post-doctoral trainees in research.

2021

ASGCT 24th Annual Meeting

May 12-15, 2021